SCHEMBL7454015

SCHEMBL7454015

COCCC(CC1(C(=O)NC2(CO)CCC(c3ccccc3)C2)CCCC1)(C(=O)O)C(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MME P08473 5/20 0.43
SIGMAR1 Q99720 4/20 0.31
HDAC4 P56524 4/20 0.31
TRPA1 O75762 1/20 0.30
ALDH1A1 P00352 1/20 0.30
LMNA P02545 1/20 0.30
RAB9A P51151 1/20 0.30
MAPT P10636 1/20 0.30
ATP1A1 P05023 1/20 0.30
ATP1B1 P05026 1/20 0.30
ATP1A3 P13637 1/20 0.30
ATP1B2 P14415 1/20 0.30
ATP1A2 P50993 1/20 0.30
ATP1B3 P54709 1/20 0.30
FXYD2 P54710 1/20 0.30
ATP1A4 Q13733 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5924951 0.84 MME (0.60) MMELMNA
SCHEMBL7447795 0.78 MME (0.70) MME
SCHEMBL7454002 0.77 MME (0.57) MMESIGMAR1
SCHEMBL7454011 0.73 MME (0.50) MME
SCHEMBL7447787 0.73 MME (0.47) MMESIGMAR1HDAC4TRPA1MAPT
SCHEMBL7447774 0.71 GPBAR1 (0.39) MMEALDH1A1LMNARAB9A
SCHEMBL7449797 0.69 MME (0.62) MME
SCHEMBL7445870 0.69 MME (0.55) MMERAB9A
SCHEMBL7450260 0.67 MME (0.48) MME
SCHEMBL23357616 0.60 S1PR1 (0.54) RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020052370-A1 Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PFIZER, INC. 2002-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052370-A1 Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase ENGASE, ENPEP, CPN1 MME 7/4885SIGMAR1 1509/4885HDAC4 1808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.